New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
20:25 EDTKO, KO, SCHW, SCHW, NTRS, NTRS, CMA, CMA, WABC, WABC, CNSI, CNSI, PBY, PBY, JNJ, JNJNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Johnson & Johnson (JNJ), consensus $1.48; Coca-Cola (KO), consensus 44c; Charles Schwab (SCHW), consensus 22c; Northern Trust (NTRS), consensus 78c; Comerica (CMA), consensus 72c; Westamerica (WABC), consensus 58c; Comverse (CNSI), consensus 49c; Pep Boys (PBY), consensus 5c.
News For JNJ;KO;SCHW;NTRS;CMA;WABC;CNSI;PBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 20, 2015
07:30 EDTJNJAchillion downgraded on valuation at JMP Securities
Subscribe for More Information
07:22 EDTKOCoca-Cola management to meet with SunTrust
Subscribe for More Information
06:39 EDTCMAComerica downgraded to Underperform at Baird
As previously reported, Baird downgraded Comerica to Underperform from Neutral and increased its price target to $44 from $40. The firm downgraded shares due to below consensus 2016 earnings estimates, and lower NIM and loan growth forecasts.
06:17 EDTJNJAchillion downgraded to Neutral from Buy at UBS
Subscribe for More Information
06:16 EDTCMAComerica downgraded to Underperform from Neutral at Baird
Subscribe for More Information
06:04 EDTPBYPotential buyers approach Pep Boys about possible takeover, WSJ reports
Pep Boys has been approached about a takeover, according to sources cited by The Wall Street Journal. The sources say Golden Gate Capital and other potential suitors have expressed interest recently in buying the company. The auto-parts and services retailer is not currently in negotiations with any of the firms and is not working with an investment bank, one source notes. Reference Link
May 19, 2015
16:10 EDTJNJAchillion enters into collaboration for HCV with Janssen
Achillion (ACHN) announced that it has entered into a worldwide license and collaboration arrangement with Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), to develop and commercialize one or more of Achillion's lead hepatitis C virus, or HCV, assets which include ACH-3102, ACH-3422, and sovaprevir. Under the terms of the agreement, Achillion will grant Janssen an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of Achillion's HCV assets. Achillion is eligible to receive a number of payments based upon achievement of specified development, regulatory and sales milestones. Achillion is also eligible to receive tiered royalty percentages between mid-teens and low-twenties based upon future worldwide sales. Janssen will be responsible for all of the development costs within the collaboration and all subsequent costs related to commercialization of the HCV assets. A key objective of the collaboration will be to develop a short-duration, highly effective, pan-genotypic, oral regimen for the treatment of HCV. An initial regimen that will be explored will feature Achillion's ACH-3102, a second-generation NS5A inhibitor currently in Phase 2 clinical studies that has been granted Fast Track designation by the U.S. Food and Drug Administration, in combination with an NS3/4A HCV protease inhibitor plus an NS5B HCV polymerase inhibitor from the collaboration. Additionally, in an equity transaction separate to the exclusive license and collaboration arrangement, Johnson & Johnson Innovation – JJDC, Inc. will invest $225M in Achillion and, in return, receive approximately 18.4M newly issued, unregistered shares of Achillion at a price of $12.25 per share. The transactions, including the equity sale, are subject to customary closing conditions, including termination or expiration of any applicable waiting periods under the Hart-Scott-Rodino Act. Transitional clinical development and technology transfer activities under the collaboration are expected to take place over the next several months.
09:02 EDTSCHWCharles Schwab lowers fees in Schwab 529 College Savings Plan
Charles Schwab announced that it is reducing fees in the Schwab 529 College Savings Plan effective July 17, 2015. The actively-managed portfolios are being reduced by an average of 20 percent, with total expense ratios now ranging from 0.41 to 1.01%, down from 0.41 to 1.34%. The passive index portfolios will decrease 45 percent to a total expense ratio of 0.30% down from 0.55%. The fee reductions are aimed at giving parents, relatives and friends an even more cost-effective way to save for a child’s higher education, a top priority for many investors as college expenses continue to rise.
08:08 EDTSCHWCharles Schwab Advisor Services change positive, says JMP Securities
Subscribe for More Information
07:13 EDTNTRSBarclays to hold a conference
Subscribe for More Information
06:40 EDTPBYGabelli adds another nominee to join board of Pep Boys
Subscribe for More Information
May 15, 2015
11:47 EDTKOAnalysts mixed on Keurig after cold drink maker unveiling
Several research firms disagreed on the outlook for Keurig Green Mountain's (GMCR) upcoming at-home cold beverage maker, Keurig KOLD, after the company unveiled the product yesterday. SunTrust and Bernstein expressed major reservations about the product, while Susquehanna was more upbeat about the device and said the shares had reached a good entry point for investors. WHAT'S NEW: Keurig's management seemed to take a cautious view on the outlook for the device's sales, Bernstein analyst Ali Dibadj wrote. Additionally, the device and its pods "seemed a bit pricey" and large. However, the analyst, noting that the company hopes to eventually cut the price of the product to $200 from $300, called a potential $200 price point "more palatable for consumers." Furthermore, Dibadj says he has a hard time "fully understanding" the company's assertion that the device solves several problems. SunTrust analyst William Chappell, Jr. was impressed by the device's technology, but said he was concerned by the product's initial price and the investments that Keurig will have to make to launch the product. He kept a Neutral rating on the shares. BULLISH OUTLOOK:, Susquehanna analyst Pablo Zuanic said that most of the information on Kold was disappointing. The analyst said that he was disappointed by the device's high price and the fact that it will take a minute to make each drink. However, noting that SodaStream's (SODA) cold drink makers have penetrated 1.5% of U.S. households, the analyst says it is "not out of the question" that Kold can reach 3% household penetration in the U.S. by fiscal 2017-2018. If Kold does attain that milestone, Green Mountain's profits would double, the analyst stated. Zuanic remained upbeat on the company's long-term outlook and says that the stock is not currently reflecting any value for Kold. He believes that the stock has reached a good entry point, and kept a $140 price target and Positive rating on the shares. WHAT'S NOTABLE: Coca-Cola (KO) owns a 16% stake in Keurig Green Mountain. PRICE ACTION: In late morning trading, Keurig Green Mountain dropped 8.3% to $94.50, while SodaStream gained 2.5% to $22.25.
08:48 EDTKOKeurig Green Mountain Keurig Cold price points worrisome, says SunTrust
After attending Keurig Green Mountain's (GMCR) Keurig Kold launch event, SunTrust says it was impressed by the device's technology but concerned about its initial price points and near-term investments needed to launch the product. The firm keeps a Neutral rating on the stock. Coca-Cola (KO) owns a 16% stake in Keurig Green Mountain. SodaStream (SODA) develops and markets at-home cold beverage makers. :
08:05 EDTKOBernstein has reservations about Keurig Green Mountain's Keurig Kold
After attending Keurig Green Mountain's (GMCR) Keurig Kold launch event, Bernstein says that it has a hard time understanding the device's value proposition and sensed some caution from the company about how quickly the device's penetration will rise and be accretive to earnings. The firm says the device and pods seem a bit expensive, while the brewer and pods are large. The firm believes that the taste of the product's Diet Coke drink was off, although regular Coke and others were good. Coca-Cola (KO) owns a 16% stake in Keurig Green Mountain. SodaStream (SODA) develops and markets at-home cold beverage makers.
07:35 EDTJNJMedivation price target raised to $148 from $128 at Leerink
Subscribe for More Information
07:13 EDTCNSIAmdocs deal can be up to 30c accretive to EPS, says Stifel
After Amdocs (DOX) agreed to buy Comverse's (CNSI) BSS business for $272M in cash, Stifel says the deal should increase Amdocs' combined operating margins by 50 basis points to 100 basis points, leading to accretion of approximately 15c-30c. The firm keeps a $60 price target and Buy rating on Amdocs.
May 14, 2015
18:41 EDTKOKeurig Green Mountain drops after Keurig Kold investor presentation
Subscribe for More Information
14:54 EDTJNJJohnson & Johnson unit reports results of VENTURE-AF trial
Subscribe for More Information
09:41 EDTJNJLeerink medical devices analyst holds a cardiology luncheon meeting
Subscribe for More Information
08:47 EDTSCHWCharles Schwab reports April net new assets totaled $9.1B
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use